Efeitos Adversos dos Inibidores da 5-Alfa-Redutase: uma revisão narrativa
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Analisar os efeitos adversos dos 5–ARIs em relação à saúde sexual e fertilidade (disfunção erétil e diminuição da libido); neurologia e psiquiatria (sintomas depressivos, automutilação e ideação suicida); endócrino, metabólico e cardiovascular (aumento da gordura corporal, LDL e colesterol total). Revisão bibliográfica: Esta revisão narrativa relata achados de vários artigos científicos publicados online, sobre os efeitos adversos dos 5-ARI's, frequentemente usados para tratar a calvície masculina e a hiperplasia benigna da próstata em homens adultos. Considerações finais: Foram identificados efeitos adversos em diversos estudos realizados em diferentes populações. Assim, é extremamente importante aumentar a conscientização pública sobre as implicações associadas ao tratamento com 5-ARI. A prescrição da terapia com 5-ARI deve ser cuidadosamente avaliada para cada indivíduo devido aos potenciais efeitos adversos que podem ocorrer no seu início e comprometer drasticamente a qualidade de vida em homens adultos.
##plugins.themes.bootstrap3.article.details##
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
2. COSKUNER ER, et al. Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors. Sexual Medicine Reviews, 2019; 7(2): 277-282.
3. DIVICCARO S, et al. Post-finasteride syndrome: an emerging clinical problem. Neurobiology Of Stress, 2020; 12: e100209.
4. FERTIG RM, et al. Sexual side efects of 5-α-reductase inhibitors fnasteride and dutasteride: A comprehensive review. Dermatology Online Journal, 2017; 11(23): 1-20.
5. GIATTI S, et al. Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin? Endocrine, 2018; 61(2): 180-193.
6. IRWIG MS. Finasteride and Suicide: a postmarketing case series. Dermatology, 2020; 236(6): 540-545.
7. KJÆRULFF TM, et al. Characteristics of finasteride users in comparison with nonusers: a nordic nationwide study based on individual level data from denmark, finland, and sweden. Pharmacoepidemiology And Drug Safety, 2020; 29(4): 453-460.
8. LEE S, et al. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: a systematic review and meta-analysis. Acta Dermato Venereologica, 2018; 99(1): 12-17.
9. LI Y, et al. The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis. Translational Andrology and Urology, 2022; 11(3): 313-324.
10. MAKSYM RB, et al. Post-finasteride syndrome – does it really exist?. The Aging Male, 2019; 4(22): 250-259.
11. MOTOFEI IG, et al. Finasteride and androgenic alopecia; from therapeutic options to medical implications. Journal Of Dermatological Treatment, 2019; 31(4): 415-421.
12. NGUYEN DD, et al. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. Jama Dermatology, 2021; 157(1): 35-42.
13. PALLOTTI F, et al. Androgenetic alopecia: effects of oral finasteride on hormone profile, reproduction and sexual function. Endocrine, 2020; 68: 688-694.
14. PEREIRA AFJR, COELHO TOA. Post-finasteride syndrome. Anais Brasileiros de Dermatologia, 2020; 95(3): 271-277.
15. SAENGMEARNUPARP T, et al. The connection of 5-alpha reductase inhibitors to the development of depression. Biomedicine & Pharmacotherapy, 2021; 143: e112100.
16. SAID MA, MEHTA A. The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men’s Health. Current Urology Reports, 2018; 19(65): 1-6.
17. TRAISH A, et al. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. Hormone Molecular Biology And Clinical Investigation, 2017; 30(3): 1-16.
18. TRAISH AM, et al. Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia. Hormone Molecular Biology and Clinical Investigation, 2015; 23(3): 85-96.
19. TRAISH AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertility And Sterility, 2020; 113(1): 21-50.
20. TRAISH AM. The Post-finasteride Syndrome: clinical manifestation of drug-induced epigenetics due to endocrine disruption. Current Sexual Health Reports, 2018; 10(3): 88-103.
21. TRÜEB M, et al. Post-Finasteride Syndrome: an induced delusional disorder with the potential of a mass psychogenic illness? Skin Appendage Disorders, 2019; 5(5): 320-326.
22. WALF AA, et al. Research Brief: self-reports of a constellation of persistent antiandrogenic, estrogenic, physical, and psychological effects of finasteride usage among men. American Journal Of Men'S Health, 2018; 12(4): 900-906.
23. WANG L, et al. Association of finasteride with prostate cancer. Medicine, 2020; 99(15): 1-8.
24. YEON B, et al. Depression risk associated with the use of 5α-reductase inhibitors versus α-blockers: a retrospective cohort study in south korea. Plos One, 2022; 17(3): e0265169.
25. ZAKHEM GA, et al. Sexual dysfunction in men taking systemic dermatologic medication: a systematic review. Journal Of The American Academy Of Dermatology, 2019; 81(1): 163-172.